Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Phenprocoumon
- Indications Stroke
- Focus Therapeutic Use
- Acronyms ReLoaDeD
- Sponsors Bayer
- 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2019 Planned End Date changed from 31 Dec 2018 to 31 Jan 2020.
- 01 Aug 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Jan 2020.